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Pramlintide in the Management of Obesity
Melissa C. Jones1, Heather F. DeBellis2 and Kimberly L. Tackett1
Associate Professor of Pharmacy Practice, 2Assistant Professor of Pharmacy Practice, Department of Pharmacy
Practice, South University School of Pharmacy, Savannah, Georgia, USA. Email: mjones@southuniversity.edu
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Abstract: Obesity is a common problem that can lead to numerous comorbid conditions, including Type 2 diabetes. Currently, there are
few pharmacologic options available to help obese patients lose weight. Pramlintide is an injectable, amylin analogue that is indicated
in patients with Type 1 and Type 2 diabetes for use in conjunction with insulin to improve glycemic control. In addition to helping
patients decrease hemoglobin A1c levels, pramlintide has also been shown to minimize weight gain, especially in patients with Type 2
diabetes. Studies have been conducted in various patient types, including those patients without diabetes, and the drug tends to have a
positive effect on weight loss. It appears that the drug is well tolerated in patients without diabetes; however, current studies have been
conducted in small patient populations. Additional research needs to be carried out to determine if the drug is a viable option for obese
patients who have failed to respond to other weight loss products.
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Obesity is a significant problem that can lead to multiple co morbid conditions. According to the Centers
of Disease Control (CDC), in 2008 only one state,
Colorado, had an incidence of obesity less than 20
percent.1 There are few approved weight loss agents
available, which has prompted researchers to look
for alternatives to treat obesity. One such product is
pramlintide. Pramlintide is an amylin analogue used
in the treatment of diabetes. Amylin analogues have
been shown to facilitate weight loss in patients with
diabetes; therefore, they may be a viable therapeutic
option in other patients where weight loss is imperative. This article will focus on the weight loss effect
of pramlintide in patients with diabetes, due to the
fact that studies in obese patients without diabetes are
minimal. However, the available studies in patients
without diabetes will be discussed.

Pramlintide

Pramlintide is classified as an amylin analogue.2
Amylin is secreted by the B-cells in the pancreas
in conjunction with insulin secretion. Like Amylin,
pramlintide suppresses hepatic glucagon secretion
leading to a decrease in hepatic glucose production.
In addition, it also slows gastric emptying, resulting
in a decrease in the amount of glucose that enters the
circulation postprandially. It also may promote a feeling of satiety, leading to a reduction in caloric intake.3
Pramlintide is administered subcutaneously and has
a bioavailability of 30%–40%. Peak plasma levels
are achieved within 20 minutes after injection and
the half-life is approximately 48 minutes. The duration of effect is 3 hours and the product is primarily
eliminated in the urine; however, dosage adjustments
in patients with renal insufficiency are not required.
Pramlintide must be given in conjunction with insulin;
however, it cannot be mixed with insulin and should
be given in a site that is away from the concomitant
insulin injection site. The initial dose in patients with
Type 2 diabetes is 60 mcg, just prior to meals, titrating
after 3–7 days to 120 mcg. When initiating therapy all
insulin doses should be decreased by 50% to avoid
hypoglycemia.

Clinical Efficacy

The main focus of this clinical efficacy section is
to highlight the weight reduction effects of amy12

lin replacement with pramlintide therapy. For this
purpose, the primary emphasis is placed on trials
evaluating pramlintide use in patients with both type1
and type 2 (insulin-treated and noninsulin-treated)
diabetes as well as in obese non-diabetic patients.
Pramlintide is currently only indicated for use in
patients with diabetes as adjunct therapy who are
using mealtime insulin and have not achieved optimal blood glucose control even with increasing insulin treatment.4

Pramlintide Use in Patients
with Type 1 Diabetes

Only about 10% of type 1 patients achieve target A1c
levels; however, intensification of insulin therapy is
usually accompanied by an increased incidence of
hypoglycemia and weight gain.5 To date there have
been three clinical trials6–8 and a pooled analysis9
evaluating pramlintide’s efficacy in type 1 diabetes
patients, which are summarized in Table 1. Long-term
clinical trials ranging from 29 to 52 weeks have
demonstrated a statistically significant weight loss
in type 1 patients. A 29-week dose escalation study
evaluated pramlintide doses ranging from 15 mcg
to 60 mcg administered with meals on changes in
weight associated with reduction in A1c.8 Doses were
titrated by 15-mcg weekly based on whether patients
reported the occurrence of nausea. Patients treated
with pramlintide plus insulin achieved a significant
reduction in mean body weight (−1.3 ± 0.30 kg)
when compared to those patients treated with placebo plus insulin (+1.2 ± 0.24 kg). A 52-week study
also demonstrated reduction in weight with the addition of pramlintide to insulin therapy in type 1 diabetes patients.7 The efficacy portion of the clinical
trial evaluated two dosages of pramlintide, 60 mcg
with meals and 60 mcg four times daily in addition
to insulin therapy. Patients treated with pramlintide in addition to insulin experienced a significant
reduction in body weight as compared to placebo
plus insulin treated patients. An additional long-term
study, published only in abstract, concluded that the
addition of pramlintide to insulin therapy improved
glucose and weight control in patients with type 1
diabetes.10
A randomized study documented weight loss in
subjects randomized to treatment with pramlintide
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8

T1DM

T1DM with A1c
7% to 8.5%

T1DM

T1DM

Patient
population

R, DB, PC, dose
escalation

Pooled analysis

R, DB, PC,
parallel-group,
MC

R, DB, parallel
study

Design

29 wk

16 to
26 weeks

52 wk

52 wk
with open
enrollment
extension to
an additional
1 year

Duration

15 mcg tid
up to 60 mcg
tid in 15 mcg
increments

30 to 60 mcg
tid or qid

a

Significance

Severe
hypoglycemiaa

-1.3 +/- 0.3 kg

1.8 kg

p  0.0001

p  0.0001

p = 0.027
p = 0.40

Tx: 0.57 ± 0.09
P: 0.3 ± 0.06

Tx: 1.4
P: 1.86

tid: 0.74 ± 0.12c
qid: 0.79 ± 0.12c
90 mcg: 0.64 ± 0.12c
P: 0.45 ± 0.09c

Double Blind Study: At Week 13,
30 mcg: 0.43 ± 0.07b
weight loss in
26 and 52 p  60 mcg: 1.24 ± 0.12
Tx group (-0.5) Open 0.001
Label Extension: Tx
group gained weight,
Placebo group lost
weight during open
enrollment

Change in weight

60 mcg tid, 60 tid: -0.4 kg
mcg qid or 90 qid:-0.4 kg 90 mcg
mcg tid
P: 0.8

30 to 60 mcg
qid

Dose

Hypoglycemia as per DCCT trial definition; bevent rate per year/standard deviation; c week 26 thru 52.
Abbreviations: R, randomized; DB, double blind; PC, placebo controlled; MC, multicenter; P, placebo group; Tx, treatment group.

n

Reference #

Table 1. Type 1 DM Table focusing on mean change in body weight from baseline.
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added on to insulin therapy.6 In the 52-week open-label
extension portion of the study, addition of pramlintide
to the patients previously randomized to placebo
resulted in a progressive reduction in mean body
weight similar to that seen in patients originally randomized to pramlintide. By week-65 of the openlabel extension, patients in both groups achieved
similar changes in weight loss, but those patients
originally randomized to the pramlintide treatment
group tended to regain weight after this week. The
lack of a placebo-control group during the open-label
extension does make it difficult to determine if this
was significant.
A pooled analysis was performed to determine
the safety and efficacy of pramlintide as adjunctive
therapy in type 1 diabetes patients.9 This analysis
concluded that the addition of pramlintide to insulin
therapy aided these patients in reaching glycemic targets without experiencing weight gain or additional
risk of hypoglycemia.

Pramlintide Use in Patients
with Type 2 Diabetes

Table 2 evaluates the clinical studies which added
pramlintide therapy to pre-existing insulin regimens
in type 2 diabetes patients. The parameters outlined
in the table include the reference, number of subjects,
patient population, study design, study duration, dose
of pramlintide administered during the trial, the mean
change in body weight from baseline, the significance,
and severe hypoglycemia incidence rates.11–15
To date, there have been three long-term clinical
trials conducted to evaluate the use of pramlintide in
insulin-treated type 2 diabetes patients.11,12,16 These studies have shown that initiating pramlintide as an adjunct
to insulin therapy augments overall blood glucose control, while abating weight gain and severe hypoglycemia, both of which are typically associated with titrating
insulin doses. The three long-term clinical studies also
showed statistically significant weight reduction at varying pramlintide doses and dosing regimens. Most notably, these studies also documented that the decrease in
A1c levels was found unrelated to the extent of weight
reduction reported. The subjects randomized in these
clinical trials are representative of a typical US type 2
diabetes patient population due to their broad range of
baseline glycemic control and body weight.
14

A pooled post hoc analysis of two long-term clinical
trials12,16 was conducted. The post hoc analysis looked
at the potential weight reduction effects of pramlintide therapy in overweight and obese insulin-treated
type 2 diabetes patients.13 They pooled patients with an
entry BMI  25 kg/m2 to determine the effectiveness
of pramlintide 120 µg twice daily given before meals
in reducing body weight. Results from this analysis
showed that roughly three times the number of pramlintide-treated patients exhibited a 5% decrease in
body weight compared to the placebo group (9% vs.
3%, p = 0.0005) as well as an associated decrease in total
daily insulin use (r = 0.39, p  0.0001). Therefore, this
analysis concluded that pramlintide as adjunct therapy
could be a potential treatment option for overweight
and obese insulin-treated type 2 diabetes patients desiring weight reduction along with resultant decreases in
total daily insulin doses.
Maggs et al carried out a pooled post hoc analysis of
two long-term clinical trials previously discussed in this
section.14 This post hoc analysis evaluated the effects
of varying pramlintide doses and dosing regimens in
Caucasian, African American and Hispanic insulintreated type 2 diabetes patients. Patients were pooled
according to their ethnicity to determine changes from
baseline to week 52 in body weight. Results illustrated a
reduction in weight for the pramlintide-treated patients
regardless of ethnicity (placebo-corrected treatment
effect at week 52: −2.6 kg, p  0.0001). This study demonstrates that there are no distinct differences between
African Americans and Hispanics when compared to
Caucasians regarding results of pramlintide treatment,
and that each of the three ethnic groups included were
positively affected by pramlintide’s ability to decrease
body weight.
A dose-escalating clinical study was conducted
to assess various pramlintide doses and dosing
regimens in basal insulin-treated type 2 diabetes
patients.15 These subjects did not reach desired glycemic control with insulin glargine alone or in combination with oral anti-diabetic agents (metformin,
sulfonylurea, and/or thiazolidinedione). Mealtime
insulin was not used during the clinical trial, so the
findings from the study can be used to determine the
effectiveness of pramlintide in patients using only
a regimen of basal insulin. This trial reported two
co primary endpoints, first the change in A1c from
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Basal
insulin-treated
T2DM

Caucasian,
African American
and Hispanic
insulin-treated
T2DM

Insulin-treated
T2DM

Insulin-treated
T2DM

Insulin-treated
T2DM

Patient
population

R, DB, PC, MC,
dose-escalating
clinical study

Pooled post hoc
analysis

Pooled post hoc
analysis

R, DB, PC, MC,
parallel-group
clinical study

R, DB, PC, MC,
dose-ranging
clinical study

Design

16 weeks

52 weeks

26 weeks

52 weeks

52 weeks

Duration

60 or 120 µg
bid/tids

120 µg bid or
150 µg tid

120 µg bid

60 µg tid,
90 µg bid,
or 120 µg bid

30 µg tid,
75 µg tid,
or 150 µg tid

Dose

-1.6 ± 0.3 kg

*Caucasian: -2.4 kg
African American:
-4.1 kg
Hispanic: -2.3 kg

-2.6 kg

-1.8 kg (Avg
difference from
placebo grp at
week 26)

120 µg: -1.1* and
-1.4* kg

90 µg: -0.7* and
-0.5 kg

75 µg: -0.5, -0.6
and -0.5
150 µg: -1.5, -1.4
and -1.3

30 µg: -0.5, -0.6
and -0.5

Change in weight

a

Hypoglycemia as per DCCT trial definition.
Abbreviations: R, randomized; DB, double blind; PC, placebo controlled; MC, multicenter; P, placebo group; Tx, treatment group.

N

Reference #

Table 2. Type 2 DM Table focusing on mean change in body weight from baseline.

p  0.0001

*p  0.0001

p  0.0001

*p  0.05

p  0.05

Significance

Tx: 44%
P: 47%

Tx: 43%
P: 40%

Did not report

90 µg: 0.1 ± 0.03
120 µg: 0.3 ± 0.05
P: 0.3 ± 0.05

30 µg: 4.1%
75 µg: 2.2%
150 µg: 2.8%
P: 1.5%

Severe
hypoglycemiaa
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baseline to week 16 as well as a dichotomous
composite endpoint evaluating the number of
patients meeting all of the following at week 16:
1) A1c  7% or an A1c reduction from baseline
0.5%, 2) mean daily postprandial glucose (PPG)
increments 40 mg/dL, 3) no weight gain, and 4)
no severe hypoglycemia. A greater number of pramlintide-treated patients than placebo group patients
reached the composite endpoint (25% vs. 7%,
p  0.001). Weight loss was noted in the pramlintide treatment group compared to the placebo group
(−1.6 ± 0.3 kg vs. +0.7 ± 0.3 kg, p  0.0001), and
no severe hypoglycemia was reported. The results
from this clinical trial concluded that glycemic and
weight control were improved by utilizing pramlintide in patients with type 2 diabetes who were
previously uncontrolled on basal insulin alone or in
combination with oral antidiabetic agents. However,
due to this clinical study’s relatively short duration
of length (only 16 weeks), other related trials need
to be conducted for these results to be considered
definitive and clinically relevant.
According to the 6 clinical trials reviewed,11–16 adding
pramlintide to varying insulin regimens in insulin-treated
type 2 diabetes patients could potentially help these
patients achieve weight loss. It appears adding pramlintide as adjunct therapy to insulin may facilitate glycemic and weight control for these patients at the expense
of increasing the amount of injections these patients
receive each day, but without increasing the risk of
severe hypoglycemia.

Pramlintide Use in Obesity

To date, there have been two clinical trials conducted
to assess the anti-obesity properties of amylin replacement with varying doses of pramlintide in patients
with diabetes.17,18 They specifically note pramlintide’s
effect on satiety and food intake in regard to the magnitude of resultant weight loss. Between the two studies,
the patient populations evaluated include obese and
nonobese insulin-treated type 2 diabetes patients, obese
noninsulin-treated type 2 diabetes patients, and obese,
healthy, patients.
A single-center, randomized, double-blind, placebocontrolled, 2-period crossover study was performed to
determine the effect of a single dose of pramlintide 120 µg
on satiety and food intake.17 Subjects randomized were
either male obese or nonobese insulin-treated type 2
16

diabetes patients (n = 14) or male obese nondiabetic
patients (n = 16). After an overnight fast, the pramlintide
or placebo dose was administered, and was followed by
a standardized preload meal which was to be ingested
within 3 minutes. The preload meal consisted of about
189 kcal, 6 g protein, 36 g carbohydrate and 3 g fat.
Then one hour after the pramlintide or placebo dose
was administered, subjects were offered an unlimited
buffet meal for the next 45 minutes. The buffet included
sandwiches, fruit, yogurt, fruit salad, custard, juice and
coffee. Energy intake, meal duration and hunger ratings
were analyzed. For the insulin-treated type 2 diabetes
patients, the total energy intake was 829 ± 72 kcal in
the placebo group and 627 ± 75 kcal in the pramlintide group. There was a reduction of 202 ± 64 kcal or
by about 23% ± 8% (p  0.01) for the insulin-treated
type 2 diabetes patients. For the obese, nondiabetic
patients, the total energy intake was 1,128 ± 81 kcal in
the placebo group and 958 ± 100 kcal in the pramlintide group. There was a reduction of 170 ± 68 kcal
or by about 16% ± 6% (p  0.02) for the obese nondiabetic patients. There was not a statistically significant
difference between the study groups in regards to meal
duration, feelings about hunger, or feelings of fullness.
During this trial, there were no reports of hypoglycemia.
The results of this trial propose that pramlintide may
be linked to a reduction in caloric intake which elicits
weight reduction. However, this study only included
a small sample size and other further studies are warranted at this time.
A randomized, double-blind, placebo-controlled,
multicenter, phase 2, dose-escalating clinical trial was
conducted to assess the anti-obesity effect of increased
doses of pramlintide in obese subjects either with
noninsulin-treated type 2 diabetes or without diabetes.18 There were 204 patients randomized to either
the placebo group (n = 67) or the pramlintide treatment group (n = 137). This four phase study consisted
of a 1-week lead in period with placebo, a 4-week
period where the pramlintide dose was increased, a
12-week maintenance period, and an 8-week follow
up period. Pramlintide treatment was initiated at 60
µg three times daily before meals and increased in
30 µg increments every 3 days to a maximum daily
dose of 240 µg. Lifestyle modification was not used
during the study. Eighty-eight percent of patients
reached a dose of 240 µg three times daily, and 8%
reached a dose of 180 µg three times daily. In contrast
Clinical Medicine Reviews in Therapeutics 2010:2
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to placebo-treated patients who did not experience a
significant weight loss, 31% of patients in the treatment group experienced a 5% weight loss at week
16 (p  0.001). At the end of the study, participants
received a questionnaire in which the majority of
the pramlintide treatment group responded that they
thought the medication helped them control their
weight and appetite, and that they believed the benefits
of the medication outweighed any problems with the
injections. They also noted that the medication made
them feel better. Even though the pramlintide doses
used in the study were higher than the recommended
dose for patients with diabetes, the most common side
effects were nausea (38%) and injection site events
(43%). Also, there were no reports of moderate to
severe hypoglycemia, only mild episodes noted (8%).
This study suggests that higher pramlintide doses are
well tolerated in obese patients.
Further research may broaden the patient population in which amylin replacement with pramlintide
therapy could be utilized as well as possibly treating
obesity in otherwise healthy patients.

Studies in Other Patient Types

Although the majority of clinical trials are conducted
in patients with diabetes, a few trials have investigated
the use of pramlintide in healthy patients. One study
was conducted in 411 obese subjects without diabetes,
BMI between 30 and 50 kg/m2 and waist circumference 102 cm for men and 88 cm for women.19 The
patients were enrolled in an initial 4 month, randomized, double-blind, placebo-controlled, dose-ranging
study and assigned to receive placebo three times per
day or pramlintide 120, 240, or 360 mcg two or three
times daily. At the end of 4 months, patients continued their pre-assigned treatment dose for an additional
8 months if they did not significantly deviate from the
protocol and agreed to the continuation. Patients also
participated in an individualized, lifestyle intervention
program throughout the trial. At the end of 4 months,
weight loss in the placebo group averaged 2.8 +/- 0.8 kg
compared to an average range of 3.8 +/- 0.7 to 6.1
+/- 0.8 kg in the treatment arms. Those patients taking 120 mcg 3 times per day and 360 mcg 2–3 times
per day achieved statistically significant reductions in
weight. In addition, waist circumference also decreased
in a number of the groups. Nausea was the most common side effect reported, with incidence increasing
Clinical Medicine Reviews in Therapeutics 2010:2

in proportion to dosing increases; however, in most
cases nausea subsided with continued use of the drug.
At 12 months, 40% of patients treated with pramlintide 120 mcg three times a day and 43% of those
treated with 360 mcg twice a day experienced a 10%
weight loss compared to 12% in the placebo group.
A few other studies have been conducted; however,
the number of patients in these studies is minimal.
A single-center, randomized, double-blind, placebocontrolled, cross-over study was conducted in fifteen healthy, normal weight subjects.20 Subjects were
exposed to a buffet meal test on two occasions. Subjects were instructed to fast overnight and the next
morning were given pramlintide 30 mcg or placebo
followed by a standardized pre-load meal. One hour
later they were offered a buffet meal at which time
caloric intake and meal duration were measured. Subjects given pramlintide had a reduced total caloric
intake of 221 +/- 101 kcal (p = 0.05) as compared to
placebo at the buffet meal. Meal duration was reduced
by 5.1 +/- 1.4 minutes (p  0.005) for patients
taking pramlintide when compared to placebo. The
study indicates that pramlintide may have an effect
on quantity of food intake and duration of meals;
thereby, adding to the evidence that pramlintide may
affect satiety.

Safety

The most common adverse event of pramlintide reported
in clinical trials of type 1 and type 2 diabetes patients
as well as obese patients without diabetes were gastrointestinal related. The incidence is higher when starting therapy with pramlintide and may be reduced with
gradual titration. Nausea was the most common event
cited in clinical trials, but anorexia and vomiting were
also reported.2,4 Nausea does have a high rate of recurrence, and is the primary reason for subject withdrawal
in pramlintide treated patients during long-term controlled trials.21
A barrier to diabetic patients maintaining tight
glycemic control, A1c of 6.5% to 7%, is fear of hypoglycemia. Prescribing information for pramlintide
does contain a boxed warning stating that pramlintide has been associated with an increased risk
of insulin-induced severe hypoglycemia in type 1
patients. This event is likely seen within three hours
following the injection of pramlintide,4,21 but clinical studies have demonstrated that pramlintide does
17
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not alter the counter-regulatory hormonal response to
insulin-induced hypoglycemia.22,23 Hypoglycemia is
the leading cause of serious adverse events reported
in both type 1 diabetes trials (9% pramlintide vs. 4%
placebo) and type 2 diabetes trials (2% pramlintide
vs. 1% placebo).21 The occurrence of hypoglycemia
in pramlintide treated patients was most common
during the first month.4 The incidence of severe hypoglycemia is reported in Table 1 and Table 2. Severe
hypoglycemia was defined per the Diabetes Control
and Complications Trials as “an event requiring the
assistance of another person, including aid in ingesting an oral carbohydrate, administering a glucagon
injection or intravenous glucose”24 in seven of the trials reviewed.

Place in Therapy

Based on the information obtained from these studies,
pramlintide may be an option for patients needing
pharmacologic assistance for weight loss; however,
further research needs to be conducted to determine
efficacy in obese patients without diabetes. There
are several drawbacks to the use of pramlintide,
including the fact that it is an injectable medication.
The medication does cause nausea in many patients
which may lead to discontinuation of the drug. In the
studies conducted, nausea was frequent; however,
it subsided over time with continued use. Symlin is
available as a SymlinPen® in strengths of 60 mcg and
120 mcg and as a multi-dose vial. The cost of the
pen is as follows: SymlinPen® 120(2 syringes, 2.7 ml
each), $293.93, which may limit its use for certain
patients.25 The cost of a multi-dose vial is less expensive, 0.6 mg/ml (5 ml, $189.74); however, it requires
a conversion from mcg to units in order to use an
insulin syringe. The conversion could attribute to
medication errors.
There are very few therapeutic options for the management of obesity. Since obesity can attribute to and
worsen numerous other medical conditions, it is impor
tant to identify products to help patients lose weight.
Pramlintide is a relatively new product that deserves
further study in order to determine if it is a viable
option for the treatment of obesity.
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